Table 2 Univariate and multivariate Cox’s proportional hazard regression models to predict pentafecta achievement.
Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
OR (95%CI) | p-value | OR (95%CI) | p-value | |
Nerve-sparing | ||||
No | Ref | Ref | ||
Yes | 5.9 (3.65,9.54) | < 0.001 | 4.16 (2.51,6.9) | < 0.001 |
Nerve-sparing technique | ||||
None | Ref | < 0.001 | Ref | < 0.001 |
Unilateral | 4.89 (3.7,7.96) | < 0.001 | 3.83 (2.31,6.37) | < 0.001 |
Bilateral | 11.93 (6.93,20.55) | < 0.001 | 7.43 (4.14,13.36) | < 0.001 |
Age group | ||||
> = 65 | Ref | |||
< 65 | 2.22 (1.69,2.92) | < 0.001 | 1.25 (0.91,1.71) | 0.166 |
PSA at diagnosis | ||||
> = 20 | Ref | Ref | ||
10–19.99 | 1.91 (0.84,4.37) | 0.125 | 1.12 (0.45,2.8) | 0.802 |
< 10 | 3.0 (0.84,6.56) | 0.006 | 1.43 (0.6,3.4) | 0.417 |
Gleason score | ||||
8–10 | Ref | Ref | ||
7 | 1.25 (0.86,1.82) | 0.238 | 1.01 (0.66,1.53) | 0.966 |
6 | 2.91 (1.81,4.69) | < 0.001 | 1.86 (1.08,3.22) | 0.026 |
Clinical T stage | ||||
3–4 | Ref | Ref | ||
2c | 3.02 (1.15,7.93) | 0.025 | 2.51 (0.84,7.5) | 0.099 |
1-2b | 4.43 (1.79,10.99) | 0.001 | 1.73 (0.6,4.99) | 0.307 |
D’Amico classification | ||||
High | Ref | Ref | ||
Intermediate | 1.4 (1.03,1.91) | 0.03 | 0.69 (0.46,1.03) | 0.071 |
Low | 2.36 (1.6,3.48) | < 0.001 | 0.73 (0.42,1.24) | 0.245 |
Neoadjuvant treatment | ||||
None | Ref | Ref | ||
ADT | 0.78 (0.49,1.24) | 0.296 | 1.67 (0.94,2.98) | 0.082 |
Anti-A | 0.55 (0.33,0.92) | 0.022 | 0.64 (0.36,1.15) | 0.139 |
NACHT | 0.48 (0.3,0.76) | 0.002 | 1.16 (0.64,2.13) | 0.623 |
Prostate volume (cm3) | ||||
< 35 | Ref | 0.569 | ||
> = 35 | 0.89 (0.6,1.33) | |||